<DOC>
	<DOCNO>NCT00002548</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy radiation therapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy radiation therapy kill cancer cell . It yet know treatment regimen effective multiple myeloma . PURPOSE : Randomized phase III trial compare effectiveness melphalan , total-body irradiation , peripheral stem cell transplantation combination chemotherapy treat patient previously untreated multiple myeloma .</brief_summary>
	<brief_title>SWOG-9321 Melphalan , TBI , Transplant v Combo Chemo Untreated Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare tumor cytoreduction achieve VBMCP ( vincristine/carmustine/melphalan/cyclophosphamide/prednisone ) v myeloablative melphalan ( L-PAM ) total-body irradiation ( TBI ) peripheral blood stem cell ( PBSC ) rescue symptomatic myeloma patient stable respond disease induction therapy VAD ( vincristine/doxorubicin/dexamethasone ) follow high dose cyclophosphamide plus filgrastim ( G-CSF ) . - Compare efficacy interferon alfa vs maintenance therapy patient achieve least 75 % cytoreduction either VBMCP myeloablative therapy PBSC rescue . - Assess allogeneic bone marrow transplantation follow myeloablative regimen L-PAM/TBI patient age 55 HLA-compatible , MLC-nonreactive donor . ( As 8/1/97 , permanent partial closure ) - Determine whether myeloablative therapy PBSC rescue extend duration survival 33 % compare result standard dose VBMCP . - Evaluate toxic effect possible long term side effect , include development myelodysplastic disease and/or acute myeloblastic leukemia , associate treatment . OUTLINE : This randomize study . Patients register 5 different point , stratification occur registration . - Registration I : Induction I - Registration II : Induction II . Patients stratify accord stage disease ( I/II vs IIIA v IIIB ) , beta-2 microglobulin diagnosis ( le 6 micrograms/mL v least 6 micrograms/mL ) , response Induction I ( 75-100 % regression v 50-74 % regression v le 50 % regression v applicable ) . - Registration III : Patients randomize allogeneic bone marrow transplant ( BMT ) ( arm close 8/1/97 ) autologous BMT . Patients stratify accord treatment receive ( high dose cyclophosphamide ( CTX ) peripheral blood stem cell ( PBSC ) prior autologous BMT v prior chemotherapy ) beta-2 microglobulin registration ( le 2 micrograms/mL v great 3 micrograms/mL v unknown ) . - Registration IV : Patients randomized maintenance therapy therapy . Those patient randomize maintenance therapy stratify accord treatment ( autologous BMT v chemotherapy v chemotherapy follow autologous BMT ) response treatment ( 75-99 % regression vs complete response ) . - Registration V : Patients receive autologous BMT registration III . Patients stratify accord prior best response ( 50 % good v less 50 % v applicable ) , duration chemotherapy ( least 6 month vs less 6 month ) , progression therapy ( chemotherapy v interferon alfa v observation ) . - Induction I : Patients receive vincristine IV doxorubicin IV continuous infusion day 1-4 dexamethasone IV orally day 1-4 , 9-12 , 17-20 . Treatment repeat every 5 week 4 course . Patients progressive disease 2 course proceed PBSC stimulation/harvest . Allogeneic BMT arm permanently close 8/1/97 . - Autologous BMT : Therapy begin 4-8 week follow high dose cyclophosphamide . Patients receive melphalan IV 1 hour day -5 total body irradiation twice day day -4 -1 . PBSC reinfused day 0 . G-CSF SQ administer begin day 1 blood count recover . - Chemotherapy : Patients receive vincristine IV , carmustine IV , cyclophosphamide IV day 1 , oral melphalan day 1-4 , oral prednisone day 1-7 . Treatment repeat every 5 week least 12 month . Patients least 75 % response autologous BMT chemotherapy randomize maintenance v therapy . Patients progress chemotherapy proceed autologous BMT ( registration V ) . - Maintenance therapy : Therapy begin 5 12 week PBSC rescue . Patients receive interferon alfa SQ three time week . Treatment continue 4 year absence disease progression unacceptable toxicity . Patients progress chemotherapy undergo autologous BMT within 8 week last course chemotherapy . Patients randomize receive therapy observe 1 year . PROJECTED ACCRUAL : A total 500 patient randomize 4 year autologous transplantation v chemotherapy follow : 250 patients/year accrue induction 200 achieve least stable disease , 125 randomize , 15 suitable donor allogeneic transplant ( 8/1/97 , allogeneic arm study close ) . Approximately 300 patient expect randomized maintenance v therapy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose , active multiple myeloma stage require treatment Smoldering myeloma ( DurieSalmon stage I ) must 25 % great increase M component level and/or BenceJones protein excretion development symptom Quantifiable M component IgG , IgA , IgD , IgE , and/or urinary kappa lambda light chain ( BenceJones protein ) excretion require Plasmacytosis least 30 % allow nonsecretory disease secretory disease without quantifiable protein IgM peak exclude Evaluation sibling potential allogeneic bone marrow transplant donor require patient 55 year age younger ( As 8/1/97 , permanently close ) HLA follow DR MLC test require Renal failure , even dialysis , eligible provide : Cause attribute myeloma ( BenceJones protein hypercalcemia ) Duration exceed 2 month If medically appropriate , follow condition treat prior registration : Pathologic fracture Pneumonia diagnosis Hyperviscosity shortness breath PATIENT CHARACTERISTICS : Age : 70 Performance status : SWOG 02 ( SWOG 3 4 base solely bone pain allow ) Hematopoietic : Not specify Hepatic : Not specify Renal : See Disease Characteristics Cardiovascular : Normal ejection fraction ECHO MUGA No myocardial infarction within 6 month No unstable angina No difficult control congestive heart failure No uncontrolled hypertension No difficult control arrhythmias No history chronic cerebral vascular accident Pulmonary : No history chronic obstructive restrictive pulmonary disease Pulmonary function study DLCO least 50 % predict except demonstrated myeloma involvement bronchoscopy and/or open lung biopsy Other : No uncontrolled diabetes No significant comorbid medical condition No uncontrolled , lifethreatening infection No prior malignancy within 5 year except adequately treat nonmelanoma skin cancer carcinoma situ cervix No prior malignancy treat cytotoxic drug use protocol Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy except local radiotherapy provide follow cumulative dose limit prior dose plus potential TBI dose protocol exceed : Less 5,000 cGy bone Less 4,000 cGy mediastinum , heart , small bowel , brain , spinal cord Less 2,000 cGy liver Less 1,500 cGy kidney lung Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>